Back to News
Market Impact: 0.2
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Enrollment has advanced to Cohort 2 in the Phase 1 trial of RPT1G for relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. The progression indicates continued clinical development, though the article provides no safety, efficacy, enrollment, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Anthropic's IPO push includes a big bet on life sciences
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat